MediPharm Labs

What MediPharm Labs does

MediPharm Labs Corp. is a Canadian pharmaceutical-grade cannabis extraction and manufacturing company headquartered in Barrie, Ontario. Founded in 2017 and listed on the TSX under the ticker LABS, the company operates a 70,000 sq. ft. GMP-certified manufacturing facility with ISO cleanrooms and holds the first Drug Establishment License issued in North America for cannabis-based APIs and pharmaceutical drug products. Its core technology stack is supercritical CO2 extraction paired with short-path wiped-film distillation (capable of >80% purity) and centrifugal partition chromatography for cannabinoid isolation, producing pharmaceutical-grade cannabis inputs rather than commodity-grade extracts.

The company operates a multi-channel B2B and B2C business model. Revenue streams include (1) bulk wholesale GMP cannabis API (concentrates, distillates, isolates) sold to licensed producers, pharma, cosmetics, food and beverage, and nutraceutical companies on quote-based multi-year contracts; (2) white label extraction, distillation, formulation, and packaging services; (3) branded consumer products (oils, soft chews, capsules, vapes, metered-dose inhalers) distributed through Canadian provincial retailers and medical cannabis channels; and (4) GMP-certified clinical trial materials supplied to academic and research institutions. Pricing for B2B is quote-based while consumer pricing is set by provincial retailers.

MediPharm distributes internationally through channel partners in 10 countries including Australia, Germany (Beacon Medical, Wildlife), France, Brazil, New Zealand, and Costa Rica (Remidose LATAM). The April 2023 all-equity acquisition of VIVO Cannabis expanded the combined entity to over CA$50M in annual revenue and added the Beacon Medical and Wildlife brands for international markets. As of Q1 2026, international medical cannabis represented 56% of total revenue and was growing 83% year-over-year. The company employs 101-250 staff, is virtually debt-free with $9.9M in cash, and recently achieved positive adjusted EBITDA under a newly appointed interim CEO.

Name

MediPharm Labs

Legal name

MediPharm Labs Corp.

Website

https://medipharmlabs.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

101–250 employees

Short description

MediPharm Labs is a Canadian GMP-certified pharmaceutical cannabis extraction and manufacturing company that produces cannabinoid APIs, white-label products, and branded consumer goods for licensed producers, provincial retailers, and international medical markets across 10 countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Cannabis Manufacturing

NAICS

Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

akta.pro secondary industry

GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL)

Keywords

• Cannabis extraction services
• Pharmaceutical cannabis manufacturing
• GMP-certified cannabis API
• White label cannabis production
• Medical cannabis distribution

Headquarters

HQ city

Barrie

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. GMP Cannabis API Wholesale: Bulk wholesale offerings including concentrate, distillate, and isolate products in various cannabinoid ratios sold to licensed producers, pharmaceutical companies, cosmetics, food & beverage, and nutraceutical companies.
2. White Label Production: Custom extraction, distillation, formulation, sensory testing, packaging, labelling, and distribution services for white label clients including licensed producers.
3. Branded Consumer Products: Pharma-quality branded products including formulated oils (CBD25, CBD50, CBD100, THC30, CBN1:2), soft chews, capsules, vapes, and inhalers sold through Canadian provincial retailers and medical channels.
4. Clinical Trial Materials: Supply of GMP-certified cannabis products for clinical trials including regulatory support documentation for Health Canada and international clinical trial applications.
5. International Medical Cannabis: Export of GMP-certified medicinal cannabis products including oils, tinctures, metered dose inhalers, and dried flower to international markets including Australia, Germany, France, Brazil, New Zealand, and Costa Rica.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Core offering

MediPharm Labs is a pharmaceutical manufacturer specializing in GMP-certified cannabis extraction, purification, and formulation, producing bulk wholesale cannabinoid active pharmaceutical ingredients (API), distillates, and isolates. The company offers white label extraction, distillation, formulation, packaging, and distribution services to licensed producers, and sells its own branded line of formulated oils, soft chews, capsules, vapes, and metered-dose inhalers through Canadian provincial retailers and international medical cannabis channels.

Differentiator

Problem solved

Functional benefit

Brands

• Beacon Medical: Medical cannabis brand serving international markets including Germany and New Zealand
• Wildlife

Products and services

• GMP Cannabis API
• White Label Cannabis Production
• MediPharm Labs Branded Consumer Cannabis Products

Quantifiable outcome

• First Drug Establishment License holder in North America for cannabis API sales
• +3 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Remidose LATAM SRLcoreChannel Partner/ Reseller/ Distributor · 13 January 2026Definitive supply agreement for export of GMP-certified medicinal cannabis products including oils, tinctures, metered dose inhalers, and dried flower into Costa Rica's newly opened medical cannabis market. Remidose LATAM holds full licensing and authorization from Costa Rican health authorities. Costa Rica's market is projected to exceed US$35 million annually.
• International Medicinal Cannabis OrganizationcoreChannel Partner/ Reseller/ Distributor · 4 December 2025Production agreement with an international medicinal cannabis organization for MediPharm's first shipment to France, marking entry into Europe's emerging medical cannabis market. The agreement enables MediPharm to meet strict European regulatory standards while expanding global footprint.
• VIVO Cannabis Inc.coreStrategic or Co-development Partner · 1 April 2023MediPharm Labs completed acquisition of VIVO Cannabis Inc. in an all-equity transaction, creating a combined entity with expanded international and Canadian market presence. The ownership ratio is approximately 73.1% for MediPharm shareholders and 26.9% for VIVO shareholders. Deal includes integration of VIVO's brands and operations with targeted annual synergies of CA$7-9 million.
• McMaster UniversitycoreStrategic or Co-development PartnerMediPharm Labs has partnered with McMaster University for multiple approved clinical trials in indications including depression-related sleep disorders, post-surgical pain treatment, and opioid sparing in chronic pain. The partnership includes provision of clinical trial materials with regulatory support documentation for Health Canada submissions.
• University Health Network (Toronto)coreStrategic or Co-development PartnerAcademic partnership with Toronto's University Health Network leveraging MediPharm's pharmaceutical experience with leading healthcare professionals researching cannabis-derived therapies.
• Loyalist CollegeminorStrategic or Co-development Partner4-year partnership commitment with Loyalist College including access to applied research opportunities, donation of $100,000 of cannabis derivatives towards study, hiring of interns, and hosting annual cohort for educational lectures. Advancing understanding of cannabis-based medicines.
• Beacon Medical / Wildlife (Germany)coreChannel Partner/ Reseller/ DistributorPartnership with German distributors Beacon Medical and Wildlife for product portfolio expansion in Germany, supporting 14% sequential revenue growth in Q1 2026.

Scale indicators15 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Canopy Growth Corporation: Canadian cannabis producer with global medical cannabis operations and CPG brands. Comparable on GMP manufacturing, branded consumer products, and international distribution, though it is in restructuring and significantly larger than MediPharm.
• Tilray Brands: Large multi-jurisdiction cannabis operator with cultivation, processing, branded products, and pharma exposure (including Manitoba Harvest and medical cannabis). Comparable to MediPharm on cannabis manufacturing and international medical distribution, though at far greater scale and with a wider product portfolio.
• Aurora Cannabis: Major Canadian licensed producer with GMP-certified cultivation, processing, and a focus on medical cannabis across Canada and Europe. Comparable on GMP manufacturing, medical cannabis focus, and international regulatory expertise.
• Cronos Group: Canadian cannabis operator with international footprint and a focus on branded products and cannabinoid research, including a strategic partnership with Altria. Comparable on GMP operations and international medical distribution, though more consumer-brand focused.
• Jazz Pharmaceuticals (GW Pharmaceuticals): Owns Epidiolex, the first FDA-approved plant-derived cannabinoid prescription drug, and operates GMP-grade cannabis botanical drug substance manufacturing. Comparable on pharma-grade cannabinoid drug manufacturing and clinical/commercial regulatory pathways.

Direct peers

• OrganiGram Holdings: Canadian licensed producer with GMP-certified manufacturing, branded consumer products, and international medical cannabis operations. Closely comparable in scale, GMP positioning, and medical/consumer split.
• The Valens Company: Canadian cannabis extraction specialist and white-label manufacturer producing cannabis concentrates, infused beverages, and pharma-grade products. Directly comparable on extraction-led business model, white label services, and B2B cannabis API offerings.
• VIVO Cannabis (now part of MediPharm): Canadian licensed producer with Canna Farms medical brand and Beacon Medical/Wildlife international brands. Acquired by MediPharm in 2023; now a subsidiary providing direct comparability on cultivation, branded products, and international medical distribution.
• Charlotte's Web Holdings: CBD-focused branded cannabis wellness products company with cultivation, extraction, and consumer product lines. Comparable on extraction-to-product manufacturing model and branded CBD/THC product portfolio in regulated markets.
• Clever Leaves: Multi-jurisdiction cannabis operator focused on GMP-certified cultivation, extraction, and B2B API/finished product supply to international markets including Europe, Latin America, and Australia. Closely comparable on B2B pharma-grade cannabis API model and international medical distribution.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/MediPharmLabs
• YouTubeyoutube.com/channel/UCudcxZJE6wAmJY1WcQDsu2w
• Facebookfacebook.com/MediPharmLabs
• LinkedInlinkedin.com/company/medipharm-labs
• Instagraminstagram.com/medipharmlabs

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MediPharm Labs